Levi Garraway, Roche CMO and EVP of global product development (Genentech)
February 7, 2023 07:33 AM ESTUpdated February 10, 03:44 AM
R&D

Roche says its C5 in­hibitor aced PhI­II head-to-head tri­als with As­traZeneca’s Soliris

Amber Tong

One of the new drugs Roche is bank­ing on for a 2023 launch has cleared two Phase III tri­als, the com­pa­ny re­port­ed.

Roche’s Genen­tech test­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

A service from the Financial Times